Education
About Us
Working with TipRanks
Follow Us
ALX Oncology Holdings (ALXO)
NASDAQ:ALXO
ALXO Stock Chart & Stats
$2.45
$0.01(0.54%)
At close: 4:00 PM EST
$2.45
$0.01(0.54%)
Day’s Range― - ―
52-Week Range$0.40 - $2.66
Previous CloseN/A
Volume579.15K
Average Volume (3M)670.12K
Market Cap
$304.38M
Enterprise Value$113.76M
Total Cash (Recent Filing)$60.63M
Total Debt (Recent Filing)$4.35M
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Feb 27, 2026EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding131,197,110
10 Day Avg. Volume555,214
30 Day Avg. Volume670,121
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.77
Price to Sales (P/S)0.00
P/FCF Ratio-0.71
Enterprise Value/Market Cap0.37
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.08
Forecast
1Y Price Target
$4.00Price Target Upside63.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
ADC Design And PayloadALX2004's moderate affinity EGFR antibody combined with a topoisomerase I payload is designed to improve therapeutic window versus earlier EGFR ADCs, supporting potential for stronger efficacy with fewer dose-limiting toxicities.
Biomarker-driven EfficacyEvidence that patients with HER2 retention and high CD47 expression have substantially better outcomes supports use of centralized CD47 testing and ctDNA-based HER2 confirmation to enrich trials and increase likelihood of meaningful responses.
Indication And Trial StrategyRefocusing on HER2-positive metastatic breast cancer and launching the Aspen-Breast trial with a planned interim readout could target a large refractory population lacking options and facilitate a faster path toward registrational data.
Bears Say
Competitive LandscapeThe growing number of topo1-containing EGFR ADC programs raises the risk of a crowded market, which could complicate differentiation and pressure commercial uptake and pricing.
Financial RunwayA limited cash runway of about one and a half years creates funding risk that may necessitate dilutive financing or partnerships before pivotal milestones are achieved.
ALX Oncology Holdings News
ALXO FAQ
What was ALX Oncology Holdings’s price range in the past 12 months?
ALX Oncology Holdings lowest stock price was $0.40 and its highest was $2.66 in the past 12 months.
What is ALX Oncology Holdings’s market cap?
ALX Oncology Holdings’s market cap is $304.38M.
When is ALX Oncology Holdings’s upcoming earnings report date?
ALX Oncology Holdings’s upcoming earnings report date is Feb 27, 2026 which is in 5 days.
How were ALX Oncology Holdings’s earnings last quarter?
ALX Oncology Holdings released its earnings results on Nov 07, 2025. The company reported -$0.41 earnings per share for the quarter, missing the consensus estimate of -$0.367 by -$0.043.
Is ALX Oncology Holdings overvalued?
According to Wall Street analysts ALX Oncology Holdings’s price is currently Undervalued.
Does ALX Oncology Holdings pay dividends?
ALX Oncology Holdings does not currently pay dividends.
What is ALX Oncology Holdings’s EPS estimate?
ALX Oncology Holdings’s EPS estimate is -0.36.
How many shares outstanding does ALX Oncology Holdings have?
ALX Oncology Holdings has 131,197,110 shares outstanding.
What happened to ALX Oncology Holdings’s price movement after its last earnings report?
ALX Oncology Holdings reported an EPS of -$0.41 in its last earnings report, missing expectations of -$0.367. Following the earnings report the stock price went up 16.949%.
Which hedge fund is a major shareholder of ALX Oncology Holdings?
Currently, no hedge funds are holding shares in ALXO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ALX Oncology Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (63.27% Upside)
$4.00 (63.27% Upside)
Insider Transactions
Bought Shares
Worth $5.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 3.5%
Last 30 Days ▲ 17.4%
Last 30 Days ▲ 17.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.66%
12-Months-Change
Fundamentals
Return on Equity
-118.95%
Trailing 12-Months
Asset Growth
-55.59%
Trailing 12-Months
Company Description
ALX Oncology Holdings
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.
ALXO Company Deck
ALXO Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented strong clinical results for evorpacept and promising progress for ALX2004. The company is well-funded and advancing its pipeline with optimism. However, there are challenges related to market positioning and historical concerns with ADCs that need addressing.View all ALXO earnings summariesALXO Stock 12 Month Forecast
Average Price Target
$4.00
▲(63.27% Upside)
Technical Analysis
Ownership Overview
10.77% Insiders
1.35% Mutual Funds
0.25% Other Institutional Investors
86.56% Public Companies and
Individual Investors